DK1558226T3 - Fremgangsmåde til cardiobeskyttelse og neurobeskyttelse ved intravenøs indgivelse af halogenerede, flygtige anæstetika - Google Patents

Fremgangsmåde til cardiobeskyttelse og neurobeskyttelse ved intravenøs indgivelse af halogenerede, flygtige anæstetika

Info

Publication number
DK1558226T3
DK1558226T3 DK03774657.5T DK03774657T DK1558226T3 DK 1558226 T3 DK1558226 T3 DK 1558226T3 DK 03774657 T DK03774657 T DK 03774657T DK 1558226 T3 DK1558226 T3 DK 1558226T3
Authority
DK
Denmark
Prior art keywords
cardioprotection
neuroprotection
intravenous administration
ischemic event
halogenated volatile
Prior art date
Application number
DK03774657.5T
Other languages
Danish (da)
English (en)
Inventor
Raul Trillo
Ralph Lessor
Satish Pejaver
Navneet Puri
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of DK1558226T3 publication Critical patent/DK1558226T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03774657.5T 2002-10-11 2003-10-09 Fremgangsmåde til cardiobeskyttelse og neurobeskyttelse ved intravenøs indgivelse af halogenerede, flygtige anæstetika DK1558226T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41793402P 2002-10-11 2002-10-11
PCT/US2003/031826 WO2004032858A2 (en) 2002-10-11 2003-10-09 Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics

Publications (1)

Publication Number Publication Date
DK1558226T3 true DK1558226T3 (da) 2012-05-07

Family

ID=32094122

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03774657.5T DK1558226T3 (da) 2002-10-11 2003-10-09 Fremgangsmåde til cardiobeskyttelse og neurobeskyttelse ved intravenøs indgivelse af halogenerede, flygtige anæstetika

Country Status (19)

Country Link
US (1) US7999011B2 (enExample)
EP (1) EP1558226B1 (enExample)
JP (1) JP5210486B2 (enExample)
KR (2) KR20120030598A (enExample)
CN (2) CN1703209A (enExample)
AT (1) ATE546136T1 (enExample)
AU (1) AU2003282464B2 (enExample)
BR (1) BR0314617A (enExample)
CA (1) CA2500310C (enExample)
DK (1) DK1558226T3 (enExample)
ES (1) ES2382911T3 (enExample)
HK (1) HK1079703A1 (enExample)
IL (1) IL167472A (enExample)
MX (1) MXPA05003741A (enExample)
NZ (1) NZ539298A (enExample)
PL (1) PL219493B1 (enExample)
RU (1) RU2350323C2 (enExample)
WO (1) WO2004032858A2 (enExample)
ZA (1) ZA200502741B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160570A0 (en) 2001-09-26 2004-07-25 Baxter Int Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
CA2921578C (en) 2002-12-24 2017-02-14 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
WO2008036858A2 (en) * 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
GB0619499D0 (en) 2006-10-03 2006-11-08 Lucent Technologies Inc Encrypted data in a wireless telecommunications system
WO2009059989A1 (de) * 2007-11-06 2009-05-14 B. Braun Melsungen Ag Einen hydrophoben wirkstoff enthaltende wässrige emulsionen
WO2009094459A1 (en) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
AU2015200210B2 (en) * 2008-01-22 2016-08-11 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
CN102006903A (zh) * 2008-01-22 2011-04-06 维波真尼克斯公司 挥发性麻醉组合物和应用方法
CA3031836A1 (en) 2009-05-05 2010-11-11 Board Of Regents, The University Of Texas System Formulations of volatile anesthetics for reducing inflammation
US20120219596A1 (en) 2009-07-30 2012-08-30 Wendelin Stark Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event
RU2408396C1 (ru) * 2009-07-30 2011-01-10 Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом
FR2956323B1 (fr) * 2010-02-15 2013-12-20 Air Liquide Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques
CN107260670A (zh) * 2011-06-24 2017-10-20 维普詹尼克斯公司 用于治疗皮肤病症或疾病的新型制剂和方法
JP6669645B2 (ja) * 2013-03-15 2020-03-18 ベイポジェニックス インコーポレイテッド 新規な鎮痛組成物
ITMO20130075A1 (it) * 2013-03-22 2014-09-23 Enrico Giuliani Dispositivo di somministrazione

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1018773A (en) * 1962-09-13 1966-02-02 Bellon Labor Sa Roger ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5635538A (en) 1993-03-16 1997-06-03 Alliance Pharmaceutical Corp. Fluorocarbon emulsions with reduced pulmonary gas-trapping properties
JP2961034B2 (ja) * 1993-09-16 1999-10-12 アルプス電気株式会社 磁気ヘッド
WO1995008544A1 (en) * 1993-09-24 1995-03-30 The University Of British Columbia Aminocyclohexylesters and uses thereof
FR2726267B1 (fr) * 1994-10-26 1998-01-02 Smithkline Beecham Lab Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
CA2416535C (en) 2000-07-26 2010-11-16 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents

Also Published As

Publication number Publication date
KR101403264B1 (ko) 2014-06-02
WO2004032858A2 (en) 2004-04-22
WO2004032858A3 (en) 2004-09-23
HK1079703A1 (zh) 2006-04-13
CN102283821A (zh) 2011-12-21
MXPA05003741A (es) 2005-06-17
ZA200502741B (en) 2006-02-22
BR0314617A (pt) 2005-08-02
US20040127578A1 (en) 2004-07-01
EP1558226A2 (en) 2005-08-03
AU2003282464A1 (en) 2004-05-04
US7999011B2 (en) 2011-08-16
NZ539298A (en) 2008-11-28
PL376217A1 (en) 2005-12-27
IL167472A (en) 2013-10-31
AU2003282464B2 (en) 2010-02-25
KR20050056230A (ko) 2005-06-14
KR20120030598A (ko) 2012-03-28
JP5210486B2 (ja) 2013-06-12
PL219493B1 (pl) 2015-05-29
ATE546136T1 (de) 2012-03-15
ES2382911T3 (es) 2012-06-14
CN1703209A (zh) 2005-11-30
JP2006504740A (ja) 2006-02-09
EP1558226B1 (en) 2012-02-22
RU2005114008A (ru) 2005-10-27
CA2500310A1 (en) 2004-04-22
EP1558226A4 (en) 2008-04-02
RU2350323C2 (ru) 2009-03-27
CA2500310C (en) 2013-03-12

Similar Documents

Publication Publication Date Title
DK1558226T3 (da) Fremgangsmåde til cardiobeskyttelse og neurobeskyttelse ved intravenøs indgivelse af halogenerede, flygtige anæstetika
Compere et al. Major complications after 400 continuous popliteal sciatic nerve blocks for post‐operative analgesia
DE69921650D1 (de) Patientenspezifische dosimetrie
JP2006501240A5 (enExample)
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
KR100535554B1 (ko) 소아과 수술에서의 레보부피바카인의 용도
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
DE60018097D1 (de) Sicherheitsmechanismus zum vorbeugen von unbeabsichtigter patienteninjektion sowie methode
Gupta et al. “Sodium bicarbonate”: an adjunct to painless palatal anesthesia
Jayakaran et al. Local anesthetics in pediatric dental practice
Alioto et al. Hematoma block for ankle fractures: a safe and efficacious technique for manipulations
Kulkarni et al. Painless anaesthesia in pediatric dentistry: an updated review
DK1638492T3 (da) Præoperativ behandling af postoperativ smerte
DE60120917D1 (de) Kombinationspräparat zur krebstherapie
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
EP1180380A3 (en) Catheter apparatus for medical treatment
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung
El Tallawy et al. Comparative study between surgical wound catheter, femoral nerve block, and adductor Canal block for postoperative analgesia after knee arthroplasty: A double blind randomized clinical trial
Padmanabhan et al. Dental Anesthesia: Can Needle-Free Injections Help
EA200600757A1 (ru) Тетрапептид, регулирующий уровень глюкозы в крови при сахарном диабете
Yaacob et al. The efficacy of xylocaine topical anaesthetic in reducing injection pain
Srivastava et al. Clinical Evaluation Of Effects Of Acupuncture Anesthesia In Extraction Of Tooth.
RU2016124135A (ru) Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
Crombez et al. Remifentanil: an attractive sedative for retrogasserian glycerol injection